EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
Article excerpt
Highlighted: the sentence this signal was extracted from
October 15, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the five-year EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative ( IHI ) and the industry partners. The research consortium is led by University Medical Center Groningen ( UMCG ) and Philips, and aims to transform how cardiovascular disease is detected, monitored and treated. It will do so by identifying and acting on three key exit points along the cardiac care journey: preventing disease before it develops ( early exit ), reversing disease progression ( mid exit ), or halting progression in advanced stages ( late exit ). Patient enrollment for the first of the 22 clinical studies will begin this month. Cardiovascular health is fundamental to overall health and well-being, yet more than 60 million people in the European Union are living with cardiovascular disease. For many, the condition significantly reduces quality of life and well-being. Without early detection, timely diagnosis and appropriate treatment, cardiovascular disease can progress silently from early risk factors to established disease and ultimately, cardiac events that may lead to premature death. "Our vision is a future where heart disease is no longer an irreversible pathway," said Professor Pim van der Harst, Project...
Keep reading with a free account
The rest of this article, and every signal for Philips, is in your free account.